Tranexamic Acid in Patients Undergoing Liver Resection: The HeLiX Randomized Clinical Trial
Paul J Karanicolas,Yulia Lin,Stuart A McCluskey,Jordan Tarshis,Kevin E Thorpe,Alice Wei,Elijah Dixon,Geoff Porter,Prosanto Chaudhury,Sulaiman Nanji,Leyo Ruo,Melanie E Tsang,Anton Skaro,Gareth Eeson,Sean Cleary,Carol-Anne Moulton,Chad G Ball,Julie Hallet,Natalie Coburn,Pablo E Serrano,Shiva Jayaraman,Calvin Law,Ved Tandan,Gonzalo Sapisochin,David Nagorney,Douglas Quan,Rory Smoot,Steven Gallinger,Peter Metrakos,Trevor W Reichman,Diederick Jalink,Sean Bennett,Francis Sutherland,Edward Solano,Michele Molinari,Ephraim S Tang,Susanne G Warner,Oliver F Bathe,Jeffrey Barkun,Michael L Kendrick,Mark Truty,Rachel Roke,Grace Xu,Myriam Lafreniere-Roula,Gordon Guyatt,HPB CONCEPT Team
DOI: https://doi.org/10.1001/jama.2024.11783
IF: 11.816
2024-08-19
JAMA
Abstract:Importance: Tranexamic acid reduces bleeding and blood transfusion in many types of surgery, but its effect in patients undergoing liver resection for a cancer-related indication remains unclear. Objective: To determine whether tranexamic acid reduces red blood cell transfusion within 7 days of liver resection. Design, setting, and participants: Multicenter randomized clinical trial of tranexamic acid vs placebo conducted from December 1, 2014, to November 8, 2022, at 10 hepatopancreaticobiliary sites in Canada and 1 site in the United States, with 90-day follow-up. Participants, clinicians, and data collectors were blinded to allocation. A volunteer sample of 1384 patients undergoing liver resection for a cancer-related indication met eligibility criteria and consented to randomization. Interventions: Tranexamic acid (1-g bolus followed by 1-g infusion over 8 hours; n = 619) or matching placebo (n = 626) beginning at induction of anesthesia. Main outcomes and measures: The primary outcome was receipt of red blood cell transfusion within 7 days of surgery. Results: The primary analysis included 1245 participants (mean age, 63.2 years; 39.8% female; 56.1% with a diagnosis of colorectal liver metastases). Perioperative characteristics were similar between groups. Red blood cell transfusion occurred in 16.3% of participants (n = 101) in the tranexamic acid group and 14.5% (n = 91) in the placebo group (odds ratio, 1.15 [95% CI, 0.84-1.56]; P = .38; absolute difference, 2% [95% CI, -2% to 6%]). Measured intraoperative blood loss (tranexamic acid, 817.3 mL; placebo, 836.7 mL; P = .75) and total estimated blood loss over 7 days (tranexamic acid, 1504.0 mL; placebo, 1551.2 mL; P = .38) were similar between groups. Participants receiving tranexamic acid experienced significantly more complications compared with placebo (odds ratio, 1.28 [95% CI, 1.02-1.60]; P = .03), with no significant difference in venous thromboembolism (odds ratio, 1.68 [95% CI, 0.95-3.07]; P = .08). Conclusions and relevance: Among patients undergoing liver resection for a cancer-related indication, tranexamic acid did not reduce bleeding or blood transfusion but increased perioperative complications. Trial registration: ClinicalTrials.gov Identifier: NCT02261415.